Acute Lymphocytic Leukemia
Johns Hopkins is home to one of the largest leukemia programs worldwide. Groundbreaking treatments in all types of leukemias and blood disorders are just the beginning of unparalleled care and commitment to our patients and families in the Johns Hopkins Leukemia Program.
Leukemia experts at Johns Hopkins are world-renowned for their experience in the treatment and management of leukemia and blood disorders.
About Acute Lymphocytic Leukemia
Acute lymphocytic leukemia most commonly occurs in children and a smaller proportion of adults. This cancer of the blood progresses rapidly and affects lymphocyte cells – immune cells that include B- and T- cells.
New Treatment Approaches
Open Leukemia Clinical Trials
Since most young adults with ALL typically do not fare as well as children with the disease, a more intensive approach to therapy is being studied through Johns Hopkins and multi-institutional clinical trials using multiple drugs and pilot studies investigating new therapies.
Combinations of experimental drugs including SNDX-275 and clofarabine are being studied at Johns Hopkins.
Johns Hopkins patients also have access to innovative clinical trials for acute leukemias and, as one of the nation’s leaders in bone marrow transplant, our clinicians have designed unique inpatient/outpatient (IPOP) programs to shorten hospital stays for select patients while maintaining the same level of expert care.